Search…

Kanghong Pharmaceutical: Self-developed KH631 eye injection has been approved for new indications and is ready for clinical use.

13/01/2026

Recently, KH631 eye injection solution of Chengdu Honghong Pharmaceutical Group Co., Ltd. subsidiary Chengdu Hongji Biotechnology Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The approved indication for this approval is "diabetic macular edema".

Latest

2 m ago

Unexpectedly, JPMorgan Chase's investment banking revenue declined in the fourth quarter, with both underwriting and mergers and acquisitions advisory fees falling.

3 m ago

Compass Point company has lowered the target price of PAYPAL from $56 to $55; upgraded the rating of Mastercard from "neutral" to "buy", and increased the target price from $620 to $735.

4 m ago

Beibu Gulf Port: plans to invest 11.403 billion yuan to build a 300,000-ton terminal project in Fangchenggang Port.

6 m ago

Kanglong Huacheng: The preliminary data shows that the net profit for the whole year is estimated to be between 1.61 billion RMB and 1.69 billion RMB.

7 m ago

The offshore Chinese Yuan to Japanese Yen exchange rate is reported at 22.79, rising over 0.4% intraday, reaching a multi-year high. With the Japanese Yen exchange rate continuing to weaken, Japanese Finance Minister Koichiro Gemba also hinted that the Japanese government is prepared to increase intervention in the exchange rate to prevent the yen from further depreciation.

See all latest